Comparative efficacy of oral, topical and intralesional acyclovir in anogenital warts

Acyclovir, a nucleoside analogue, is an antiviral agent and have shown efficacy as an intralesional agent in warts. Hence may be used for anogenital warts in various administrations. Forty-five consecutive patients of anogenital warts will be recruited for the study and divided into 3 groups of 15 each. Group A patients will be given oral acyclovir in the dose of 400mg thrice a day for 4 weeks. Group B patients will be given topical 5 percent acyclovir cream thrice a day for 4 weeks. Group C patients will be given intralesional acyclovir 70mg per ml once a week for 4 weeks. Each patient shall be followed every week for 4 weeks of therapy and also at additional 4 weeks of stoppage of therapy. Clinical response will be documented at each visit by evaluating the decrease in lesion count, decrease in size of lesions an presence of any side effects.